Chief Executive Officer
Aman Wasan is the CEO of ArisGlobal. Aman is a Scientist by training with a degree in Human Genomics. He has a deep knowledge of the Life Sciences industry, a well-established background in global leadership roles, and an expert in operational management and commercial leadership. Prior to taking the role of CEO, Aman served as Chief Commercial Officer for ArisGlobal, where he managed our commercial business and significantly scaled revenue. Since joining ArisGlobal in 2018, Aman has excelled in six different positions, including that of Head of Pharmacovigilance. Before joining the ArisGlobal team, Aman worked for Bioclinica as the company’s Global Head of Safety and Regulatory Services.
Glenn brings more than 15 years of executive leadership across various industries. He has a strong background in scaling and supporting software and services businesses, as well as extensive M&A experience, including multiple exit transactions, public offerings, and acquiring and integrating new entities.
Before joining ArisGlobal, Glenn served as the CFO of Paya, an integrated payments company, where he led the team through a public listing and through its ultimate sale to Nuvei Corporation. Prior to that role, he was the CFO of Opus Global, a Risk & Compliance SaaS company serving the Fortune 100. At Opus Glenn was part of the management team that closed the transaction for the sale of Opus’ third-party risk management platform to Coupa Software. Glenn started his career at General Electric where he completed GE’s Financial Management Program.
Ann-Marie brings more than 30 years of expertise to the ArisGlobal team and as CIO plays a pivotal role in driving the company’s technological development, fostering a results-driven culture, advising on the best solutions to stay ahead of the competition, optimizing processes, and capitalizing on emerging opportunities.
Ann-Marie came to ArisGlobal from TransUnion Euro, where she served as Chief Information Officer (CIO), leading and delivering the technology integration of Callcredit into TransUnion. She has a strong background in transforming the end-to-end technology lifecycles, leading global IT transformational projects, system integrations, and migration of products from on-premise to cloud, such as Azure and AWS.
Julie is a seasoned marketing executive with over 30 years of experience in corporate, business and consumer marketing. She has a proven track record driving transformational business objectives, specifically on exits from private equity to the public market. She has contributed to M&A efforts, IPOs, and other strategic business initiatives, including leading all marketing and communications of TransUnion’s 2015 successful IPO. She has held leadership positions at other organizations such as Fast Radius and Experian where she led companywide projects in brand and reputation, performance and revenue, net promoter score, and change management.
Steve has a wealth of experience and a proven record of success in executive roles across the life sciences and healthcare technology sectors. He joined us from DNAnexus, a premier genomic data technology company, where he served as Chief Commercial Officer. Under his guidance, DNAnexus saw notable growth and innovation, with a strategic focus on supporting pharma, clinical diagnostics, and academic medical centers.
Previously, Steve served as Chief Revenue Officer at ArisGlobal for two years, significantly contributing to our growth and development. Before this, he was EVP and Chief Commercial Officer at ERT (now Clario), where as part of the original leadership team, he was instrumental in transforming and rapidly growing the company.
As senior vice president and head of global consulting, Raj Hattarki is responsible for ensuring customer success globally and leading global consulting team.
With more than 20 years of experience in life sciences leading cloud technology companies, he started his life sciences industry journey with ArisGlobal in software engineering and ascended into leading Professional Services for North America. Raj has built high performing teams driving technology transformations for many of the renowned Pharmaceutical, Biotech, Medical Device and CRO companies globally.
Prior to joining ArisGlobal as his second tenure, Raj worked with Veeva Systems and lead their Vault Safety services practice. Raj holds an Engineering degree from Gulbarga University, India.
Ritu has more than twenty-five years of industry experience across various domains ranging from Lifesciences, BFSI & Automobile. She has been with ArisGlobal for 12 years and currently serves as the Chief of Staff to the CEO, along with heading Global Partnerships and Quality Assurance function. She provides strategic and operational support to the executive team, Board of Directors, and department heads in driving key organizational-level initiatives.
Prior to joining ArisGlobal, she worked with large IT organizations, including Oracle and Tata Consultancy Services. Ritu is a B.Tech in Electrical Engineering From NIT, Bhopal, India and holds an Executive MBA from the Univ. of Chicago Booth School of Business.
Daniel Berglund is a member of ArisGlobal’s Board of Directors and a Partner at Nordic Capital, having joined the firm in January 2010. Daniel has served on the boards of nine Nordic Capital portfolio companies. Daniel focuses on investment situations within Technology and Payments as well has Healthcare IT. Before joining Nordic Capital, Daniel worked at Bain & CO from 2007 to 2009, most recently as a Senior Associate. Daniel holds an MSc in Economics from the Stockholm School of Economics and Business Administration from the Ross School of Business at the University of Michigan.
Eric Jensen is a member of ArisGlobal’s Board of Directors and a Managing Director in the Operations Advisory Group at Nordic Capital. Previously, Eric was an entrepreneur and operator, serving as Chief Product Officer of AVIA, a digital health professional services firm which he co-founded, and as EVP of Health Systems Products and Strategy at Healthgrades. Eric started his career at McKinsey & Company where he served healthcare services clients as an Associate Partner. Eric holds an MBA from the University of Michigan and a B.S. degree in Chemical Engineering from The Ohio State University.
Spencer Michelson is a member of ArisGlobal’s Board of Directors and a Manager at Nordic Capital, having joined the firm in September 2022. Spencer has been deeply involved with seven different portfolio companies as a private equity investor, including three since he joined Nordic Capital. Prior to Nordic, Spencer was an investor for three years at GTCR, a private equity firm based in Chicago, IL, and an investment banker at Credit Suisse. Spencer holds an AB degree in Public & International Affairs from Princeton University.
Rob is currently on the board of Confo Therapeutics, Draupnir Bio, Oncospherix, WindTree Therapeutics, Redx Pharma and Variant Bio. He is also on the scientific and strategic advisory boards of Variant Bio, Cytel, Inflexion, Orange Grove Bio and BioEthics International. Rob is part time Chief Medical Officer of Abionyx.
Subscibe to our
Oops! We could not locate your form.
ArisGlobal is a pivotal partner in the life sciences industry, specializing in solutions that drive drug development, safety monitoring, and regulatory compliance. We collaborate with more than 500 global life sciences companies, CROs, and government health authorities, including leading biopharmaceutical firms and regulatory bodies such as FDA, Health Canada, and NMPA.
Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China.
Quick Links
© 2024 ArisGlobal – All Rights Reserved